of population will be
diagnosed with cancer
at some point during their
lifetimes.
Sumaq Life LLC is currently working with research partners at Texas A&M University to develop an explainable AI approach to design personalized cancer treatment. Explainable AI uses models of complex gene regulatory networks involved in cancer development to target therapy with a better likelihood of success.
These models have been used to identify key drug targets that have demonstrated remarkable success in achieving robust cancer cell killing in several aggressive cancer cell lines, including metastatic melanoma1, osteosarcoma2, breast3, pancreatic4, lung5, and colorectal6 cancer.
Cancer Gene Regulatory Network Models
Explainable AI Software
Patient:
Providers:
Payors:
Pharmaceutical Companies:
Unlock life opportunities through scientific discovery.
Sumaq Life was formed to create health-related technological innovations and increase translation of scientific discoveries into real-world applications.
Great scientific discoveries are not always translated to society. Equally important to strong scientific justification is a viable translation pathway. Sumaq Life serves as a translation vehicle to ensure the impact of scientific discoveries are realized.
SUMAQ LEADERSHIP TEAM
Dr. N. Peter Reeves, PhD
President and FounderDr. Reeves has a PhD in Biomedical Engineering from Yale University (2007) and is an established researcher specializing in modeling complex biological systems. He has +60 peer-reviewed publications and has served as a PI/Co-PI on approximately $5M in federally funded research.
Patricia Gonzales-Lazarte, LLM
Chief Financial OfficerMrs. Gonzales-Lazarte completed her law degree from the University of Lima (Peru), specializing in Corporate Law, and has a Master's in Law from the University of British Columba. She has worked for over 10 years in international consulting firms (Arthur Andersen, BDO), where she advised large national and international corporations on business and tax matters.
Dr. Rachad Al Ameen, MBA/PharmD
Business StrategistDr. Al Ameen received is Doctor of Pharmacy from Wayne State University in 2017 and worked as a clinical pharmacist for CVS Health and later established and managed an independent pharmacy. In 2022, he completed a MBA, with an emphasis on entrepreneurship and finance, from the University of Michigan Ross School of Business.
SUMAQ AVISORY BOARD
Prof. Aniruddha Datta
J. W. Runyon, Jr. '35 Professor II of Electrical and Computer Engineering at Texas A & M University. A control engineer by training, he successfully retrained in the area of Cancer Genomics under a 2-year National Cancer Institute Training Grant (2001-2003). Since then, his NSF-funded research has focused on utilizing engineering approaches for cancer therapy design, including gene regulatory modeling.
Dr. Giuseppe Del Priore
A practicing oncologist and clinical researcher at Morehouse School of Medicine (>100 peer-reviewed publications). Dr. Del Priore has a Master’s in Public Health in biostatistics and epidemiology, and currently practices at a tertiary care, safety net hospital in inner city Atlanta (Grady Hospital) and a community health center.
Mr. Brian Decker
CEO and Founder of EMOL Health, a medical software company servicing over 315 oncology sites in 30 US states with a growing oncology database of over 4.4 million unique cancer patients. Mr. Decker has an undergraduate degree in computer science from Michigan Technology University and an MBA from the University of Notre Dame.
